Literature DB >> 17346843

Development of a fed-batch process for the production of the cytochrome P450 monooxygenase CYP102A1 from Bacillus megaterium in E. coli.

Simon Pflug1, Sven M Richter, Vlada B Urlacher.   

Abstract

A fed-batch process utilizing a pET-based expression system (pET28a+ derivative) and E. coli BL21(DE3) as production strain for the heterologous expression of recombinant cytochrome P450 monooxygenase CYP102A1 from Bacillus megaterium was developed. In a first step the expression was optimized during a series of flask experiments testing several parameters for their influence on the expression level, activity and solubility of the recombinant protein. The optimal process parameters found in the flask experiments were transferred to a cultivation process in a 5l (operating volume) bioreactor with a special focus on the feeding strategy and the aeration during expression. Glycerol feeding proved to be superior over glucose as carbon source since the formation of larger amounts of acetate was prevented. Expression levels exceeding 12,500nmoll(-1), corresponding to approximately 1.5gl(-1) of product in culture medium ( approximately 11% of CDW) could be demonstrated. The P450 enzyme showed high activity and high solubility. The findings now can be transferred to other enzyme variants and different P450 monooxygenases to increase production of recombinant proteins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17346843     DOI: 10.1016/j.jbiotec.2007.01.013

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  9 in total

1.  Use of a stress-minimisation paradigm in high cell density fed-batch Escherichia coli fermentations to optimise recombinant protein production.

Authors:  Chris Wyre; Tim W Overton
Journal:  J Ind Microbiol Biotechnol       Date:  2014-07-24       Impact factor: 3.346

2.  Recombinant hemoglobin II from Lucina pectinata: a large-scale method for hemeprotein expression in E. coli.

Authors:  Cacimar Ramos; Ruth Pietri; Wilmarie Lorenzo; Elddie Roman; Laura B Granell; Carmen L Cadilla; Juan López-Garriga
Journal:  Protein J       Date:  2010-02       Impact factor: 2.371

3.  An efficient light-driven P450 BM3 biocatalyst.

Authors:  Ngoc-Han Tran; Daniel Nguyen; Sudharsan Dwaraknath; Sruthi Mahadevan; Garrett Chavez; Angelina Nguyen; Thanh Dao; Sarah Mullen; Thien-Anh Nguyen; Lionel E Cheruzel
Journal:  J Am Chem Soc       Date:  2013-09-19       Impact factor: 15.419

4.  Using small molecules as a new challenge to redirect metabolic pathway.

Authors:  Dina Morshedi; Farhang Aliakbari; Hamid Reza Nouri; Majid Lotfinia; Jafar Fallahi
Journal:  3 Biotech       Date:  2013-11-30       Impact factor: 2.406

5.  Development of fed-batch profiles for efficient biosynthesis of catechol-O-methyltransferase.

Authors:  G M Espírito Santo; A Q Pedro; D Oppolzer; M J Bonifácio; J A Queiroz; F Silva; L A Passarinha
Journal:  Biotechnol Rep (Amst)       Date:  2014-05-27

Review 6.  Oxygenating Biocatalysts for Hydroxyl Functionalisation in Drug Discovery and Development.

Authors:  Sacha N Charlton; Martin A Hayes
Journal:  ChemMedChem       Date:  2022-05-02       Impact factor: 3.540

7.  The influence of microbial physiology on biocatalyst activity and efficiency in the terminal hydroxylation of n-octane using Escherichia coli expressing the alkane hydroxylase, CYP153A6.

Authors:  Oluwafemi A Olaofe; Caryn J Fenner; Rama Krishna Gudiminchi; Martha S Smit; Susan T L Harrison
Journal:  Microb Cell Fact       Date:  2013-01-25       Impact factor: 5.328

Review 8.  Optimization of the bacterial cytochrome P450 BM3 system for the production of human drug metabolites.

Authors:  Giovanna Di Nardo; Gianfranco Gilardi
Journal:  Int J Mol Sci       Date:  2012-11-28       Impact factor: 5.923

9.  Synthesis of ω-hydroxy dodecanoic acid based on an engineered CYP153A fusion construct.

Authors:  Daniel Scheps; Sumire Honda Malca; Sven M Richter; Karoline Marisch; Bettina M Nestl; Bernhard Hauer
Journal:  Microb Biotechnol       Date:  2013-08-14       Impact factor: 5.813

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.